Eli Lilly's New Weight-Loss Drugs Show Promising Results in Phase 3 Trials
TL;DR Summary
Eli Lilly's new obesity pill helps patients maintain weight loss after switching from injections like Wegovy and Zepbound, with promising trial results suggesting it could serve as a needle-free long-term treatment option, potentially capturing significant market share in the growing weight loss drug industry.
- Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound CNBC
- People Are Already Taking This Unapproved New Weight-Loss Drug WIRED
- Major Weight Loss and Knee-Pain Relief Seen With New Eli Lilly Drug The New York Times
- Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial Yahoo Finance
- Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company Eli Lilly
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
4 min
vs 4 min read
Condensed
94%
773 → 44 words
Want the full story? Read the original article
Read on CNBC